Program overview: Health and well-being are intrinsically impacted by socio-determinants related to carers, family, community, and service delivery across health and other sectors, within local country context. Socio-determinants are complex and can include dispossession, institutional racism, drug and alcohol, and debt, resulting in a lack of access to culturally safe services and intergenerational mistrust of services. However, sustainably integrating services within health and other sectors is challenging due to patient, organisational and policy and historical barriers.Our program aims to strengthen health systems resilience using interdisciplinary implementation research across different contexts, cultures and sectors, to holistically address socio-determinants of health so as to improve health equity. Program Objectives:  Examine and implement best practices in community engagement, partnerships and capacity-strengthening.  Embed WHO integrated people-centred

What are clinical trials? Clinical trials are research studies with humans, designed to test new treatments to find better ways to prevent, detect or treat disease1. Clinical trials are also sometimes referred to as interventional trials. The sorts of treatments being investigated include medicines or drugs, cells and other biological products, surgical procedures, radiologic procedures, devices, behavioural treatments, process-of-care changes, preventive care, and other items.2 Clinical trials rely on having members of the general public agree to take part. What happens in a clinical trial? In a clinical trial, participants meet with researchers who go through what the clinical trial will involve. All participants must be advised about the objectives of the research, what is expected of them, as well as any risks that may be experienced during and after the trial. Trials must follow a carefully controlled protocol, which is a plan that describes what researchers will do in the stu

Researchers at The George Institute for Global Health, UK, led by Executive Director Professor Otavio Berwanger, are spearheading a programme of work to transform that way we deliver large-scale clinical trials. This programme is borne out of a recognition of the limitations of the ‘traditional’ clinical trial model – and the health gains (social, environmental and economic) – to be had in investigating pragmatic, innovative and efficient approaches. In both the so-called ‘traditional’ and innovative trial models, the gold standard of randomisation controls for both known and unknown confounding factors that could influence trials outcomes, and represents the optimal method to work out whether a healthcare intervention reduces the risk of patient-important outcomes and so inform clinical practice. Where the two models differ is that the traditional approach requires participants be screened and recruited in a trial site by a team of investigators, and so demands both a

Soul Patts nurtures our future tech leaders to bring game-changing health solutions to life.

The George Institute’s founders are building on their pioneering vision with a transformational, million-dollar investment.